Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
N Z Med J ; 134(1530): 38-47, 2021 02 19.
Artículo en Inglés | MEDLINE | ID: mdl-33651776

RESUMEN

AIMS: We aimed to assess the use of and attitudes towards cannabis use (medicinal and recreational) by people with IBD in New Zealand. METHODS: People with IBD were invited to complete an anonymous online questionnaire. Participants were recruited via postal mail using a hospital database of patients with IBD (developed by the Gas-troenterology Department at Dunedin Public Hospital) and via online recruitment (advertised on the Crohn's and Colitis New Zealand website, Facebook page and e-mail list). Inclusion criteria were ages 18+ and self-reported confirmed IBD diagnosis. RESULTS: In total, 378 participants completed the questionnaire, with 334 eligible responses. Partici-pants were predominantly New Zealand European (84%) and female (71%). Sixty-one percent of re-spondents had CD and 34% UC. Overall, 51% of respondents reported having ever used cannabis. Of those, 63% reported use as recreational and 31% for reduction of IBD symptoms. Users were more likely to be younger (on average by 6.4 years), with on-going symptoms, unemployed or self-employed and current or ex-smokers. There were no differences by disease status or severity. Symp-toms most reported as improved by cannabis use were abdominal pain/cramping, nausea/vomiting and loss of appetite. Fifty-four percent of participants reported that if cannabis were legal, they would request it for medicinal use to help manage their symptoms. CONCLUSIONS: Overall, our research aligns with previous observational research that reports im-provements in symptoms of IBD with cannabis use. Studies of a higher evidence level (eg, RCTs) would be needed to guide prescribing. In the meantime, this research provides useful background to clini-cians about patients' views and experiences.


Asunto(s)
Actitud , Cannabis/efectos adversos , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Fitoterapia/estadística & datos numéricos , Adolescente , Adulto , Anciano , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/psicología , Enfermedad de Crohn/tratamiento farmacológico , Enfermedad de Crohn/psicología , Utilización de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Enfermedades Inflamatorias del Intestino/psicología , Masculino , Persona de Mediana Edad , Nueva Zelanda , Fitoterapia/métodos , Extractos Vegetales/uso terapéutico , Automedicación/estadística & datos numéricos , Autoinforme , Adulto Joven
2.
Epidemiology ; 25(6): 811-22, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25207954

RESUMEN

BACKGROUND: Maternal prenatal supplementation with folic acid and other vitamins has been inconsistently associated with a reduced risk of childhood acute lymphoblastic leukemia (ALL). Little is known regarding the association with acute myeloid leukemia (AML), a rarer subtype. METHODS: We obtained original data on prenatal use of folic acid and vitamins from 12 case-control studies participating in the Childhood Leukemia International Consortium (enrollment period: 1980-2012), including 6,963 cases of ALL, 585 cases of AML, and 11,635 controls. Logistic regression was used to estimate pooled odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for child's age, sex, ethnicity, parental education, and study center. RESULTS: Maternal supplements taken any time before conception or during pregnancy were associated with a reduced risk of childhood ALL; odds ratios were 0.85 (95% CI = 0.78-0.92) for vitamin use and 0.80 (0.71-0.89) for folic acid use. The reduced risk was more pronounced in children whose parents' education was below the highest category. The analyses for AML led to somewhat unstable estimates; ORs were 0.92 (0.75-1.14) and 0.68 (0.48-0.96) for prenatal vitamins and folic acid, respectively. There was no strong evidence that risks of either types of leukemia varied by period of supplementation (preconception, pregnancy, or trimester). CONCLUSIONS: Our results, based on the largest number of childhood leukemia cases to date, suggest that maternal prenatal use of vitamins and folic acid reduces the risk of both ALL and AML and that the observed association with ALL varied by parental education, a surrogate for lifestyle and sociodemographic characteristics.


Asunto(s)
Ácido Fólico/administración & dosificación , Leucemia Mieloide Aguda/epidemiología , Leucemia Mieloide Aguda/prevención & control , Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevención & control , Vitaminas/administración & dosificación , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Suplementos Dietéticos , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Intercambio Materno-Fetal , Embarazo , Riesgo , Factores de Riesgo
3.
Trop Med Int Health ; 14(2): 149-55, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19171012

RESUMEN

OBJECTIVE: To investigate the relationship between child mortality and common preventive interventions: vaccination, trained birthing attendants, tetanus toxoid during pregnancy, breastfeeding and vitamin A supplementation. METHODS: Case-control study in a population under demographic surveillance. Cases (n = 141) were children under five who died. Each was age and sex-matched to five controls (n = 705). Information was gathered by interviewing primary caregivers. RESULTS: All but one of the interventions - whether the mother had received tetanus toxoid during pregnancy - were protective against child mortality after multivariate analysis. Having a trained person assisting at child birth (OR 0.2 95% CI 0.1-0.4), receiving all vaccinations by 9 months of age (OR 0.1; 95% CI 0.01-0.3), being breastfed for more than 12 months (Children breastfed between 13 and 24 months OR 0.1 95% CI 0.03-0.3, more than 25 months OR 0.1 95% CI 0.01-0.5) and receiving vitamin A supplementation at or after 6 months of age (OR 0.05; 95% CI 0.01-0.2) were protective against child death. CONCLUSIONS: This study confirms the value of at least four available interventions in the prevention of under-five death in The Gambia. It is now important to identify those who are not receiving them and why, and to intervene to improve coverage across the population.


Asunto(s)
Mortalidad del Niño , Mortalidad Infantil , Servicios Preventivos de Salud/métodos , Lactancia Materna/estadística & datos numéricos , Cuidadores , Estudios de Casos y Controles , Preescolar , Femenino , Gambia/epidemiología , Humanos , Lactante , Recién Nacido , Masculino , Partería/métodos , Análisis Multivariante , Embarazo , Toxoide Tetánico/uso terapéutico , Vacunación , Vitamina A/uso terapéutico
4.
BMC Public Health ; 7: 136, 2007 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-17605825

RESUMEN

BACKGROUND: An earlier case-control study from Western Australia reported a protective effect of maternal folic acid supplementation during pregnancy on the risk of childhood acute lymphoblastic leukaemia (ALL). The present study tested that association. METHODS: A national case-control study was conducted in New Zealand. The mothers of 97 children with ALL and of 303 controls were asked about vitamin and mineral supplements taken during pregnancy. RESULTS: There was no association between reported folate intake during pregnancy and childhood ALL (adjusted odds ratio (OR) 1.1, 95% confidence interval (CI) 0.5-2.7). Combining our results with the study from Western Australia and another study from Québec in a meta-analysis gave a summary OR of 0.9 (95% CI 0.8-1.1). CONCLUSION: Our own study, of similar size to the Australian study, does not support the hypothesis of a protective effect of folate on childhood ALL. Neither do the findings of the meta-analysis.


Asunto(s)
Suplementos Dietéticos/estadística & datos numéricos , Ácido Fólico/uso terapéutico , Hierro de la Dieta/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevención & control , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Modelos Logísticos , Minerales/uso terapéutico , Nueva Zelanda/epidemiología , Embarazo , Medición de Riesgo , Factores de Riesgo , Encuestas y Cuestionarios , Resultado del Tratamiento , Vitaminas/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA